- NCIt
- C40242
Loading cancer entity…
Loading cancer entity…
Clinical trials
18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT01735006 | Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine | completed | Phase 3 | 7,372 | Xiamen UniversityOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT02562508 |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials
| A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls |
| completed |
| Phase 3 |
| 979 |
| Jun ZhangOTHER |
| 1 |
| Aug 16, 2018 |
| clinicaltrials |